The Hydration Pharmaceuticals Company Limited

Hydralyte Partners With Roolife To Expand Global Distribution Footprint In China

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to announce it has appointed e- commerce company RooLife Group Ltd (“RooLife”) (ASX:RLG) to exclusively market, sell and distribute its leading range of Hydralyte products in China.


HIGHLIGHTS

  • HPC confirms the appointment of ASX-listed RooLife Group (ASX:RLG) to market, sell and distribute the Hydralyte range of electrolyte-rich tablets, liquids and powders in China.
  • The appointment aligns strategically with the Company’s aim to expand the global addressable market for Hydralyte North America products through targeted partnerships.
  • Under the terms of the agreement, RLG will manage digital marketing and e-commerce store operations with exclusive distribution rights for Hydralyte products across online and physical stores.
  • Distribution partnership aims to leverage the high profile of Australian health & wellness products to drive increased brand awareness in China through RLG’s extensive network of China-based distribution partnerships across e-commerce and physical stores.
Under the terms of the agreement, RooLife has contracted to provide digital marketing, social media operations and e-commerce store operations, with exclusive distribution rights for Hydralyte North America products across online and physical store sales, including cross border e-commerce and general trade in China.

The distribution agreement with RooLife aligns with HPC’s strategy to expand the global addressable market for its leading product range through a targeted partnership approach that seeks to leverage the respective strengths of both parties.

The Company’s decision to partner with RooLife provides Hydralyte North America with a unique access point to the Chinese consumer market through RLG’s existing distribution channels, which have been established over a long period of time in accordance with rigorous compliance standards for imported goods.

With its established presence in China, RLG expects to provide Hydralyte North America with direct and immediate access to an expanded group of sales channels and the capacity to scale up further through additional distribution partnerships as they occur.

The broader distribution networks provided through RooLife will comprise both e-commerce and bricks & mortar retailers, complementing HPC’s existing agreement with Alibaba subsidiary Tmall.

The distribution process for Hydralyte products into China also has the potential to be accelerated due to the fact that Hydralyte North America products are classified as a food product rather than a supplement, which allows for a simpler regulatory pathway to gain import approval for the Chinese market.

Strategically, the agreement with RooLife has been assessed by the Hydralyte North America Board and management team as a distribution opportunity that could provide the Company with potentially material upside with minimal downside risk from an operations and capital management perspective.

Under the terms of the agreement, RLG will provide digital marketing and social media management services along with operations management for e-commerce. RLG will receive a margin on all Hydralyte products sold in accordance with the terms of the agreement.

The agreement with RooLife is for a 2 year and 5-month term (Term) with the ability for the Term to be extended by 1 year by mutual written agreement by the parties. The remaining terms of the agreement are considered commercially sensitive.

The economic materiality of the agreement with RLG is unknown due to the uncertainty in sales outcomes and no minimum sales order requirements. However, the Company expects that entering into a partnership with RLG may have a material impact on the Company’s business development prospects and global distribution opportunities.

Management commentary:

Chief Executive Officer Mr Oliver Baker said: “RLG’s well-established online sales channels and access to growing physical store network is the perfect platform to enter the large China market.

Their highly capable sales & marketing offering and understanding of how to sell and promote a product to Chinese consumers presents us with a very unique opportunity to establish the Hydralyte brand here.”

RooLife Group CEO, Bryan Carr added: “We are excited to add such a high-profile and proven brand as Hydralyte to our healthy, functional food and beverage portfolio in China where we continue to grow out our online and physical store channels, servicing the high consumer demand for quality international products with China’s large, emerging middle class. We look forward to working with Hydralyte’s very dynamic team, extending their global sales footprint considerably by leveraging the growing awareness of health and wellness generally in China and the established trust and awareness for Australian-founded wellness brands, making Hydralyte a great match for RLG and our capabilities in China.”

About RooLife Group: RooLife Group is a cross-border distribution platform that matches leading international brands and products with the key trends in Chinese consumer demand. The Company has built an extensive network of distribution channels across ecommerce and traditional retail in the Chinese market and complements its service offering with fully integrated digital market and customer acquisition services. RooLife’s online eCommerce marketplaces assist businesses to sell directly to Chinese consumers with integrated payment solutions via the WeChat and Alipay platforms. RLG serves a broad range of international clients from Australia and other jurisdictions including New Zealand, Europe, the UK and the United States.


Click here for the full ASX Release

This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Hydralyte International (ASX:HPC)

Hydralyte International


Keep reading...Show less
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al. No. 2:22-cv-497 and Houlihan v. Kawas et al ., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.

  • Praxis management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference, taking place in New York, NY at the NASDAQ Stock Exchange on May 20, 2024 at 10:00am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

  • Praxis management will also participate in the Mizuho Securities USA Neuroscience Summit, taking place in Boston, MA on May 21, 2024.

  • Praxis management will also be participating in a fireside chat at the Jefferies Global Healthcare Conference, taking place in New York, NY on June 6, 2024 at 11:30am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 52,590 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $4.50, which was the closing price of Annexon's common stock on May 15, 2024, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2 nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

Event H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Date May 20th, 2024
Time 12:00 PM Eastern Time
Link Fireside Chat [ Link ]

About Nuvectis Pharma, Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "We reached an important clinical development milestone in the first quarter of 2024.  Enrollment was completed in two ongoing clinical trials to evaluate HCW9218 in solid tumors.  We are encouraged by the number of patients with evidence of stable disease, even though it is difficult of generalize from Phase 1 and Phase 1b results. We are following our strategy to participate in fully randomized Phase 2 clinical trials in difficult-to-treat cancer indications, working with leading clinical sites.  Using this strategy, we believe we can cost effectively evaluate HCW9218 as a single arm in a larger study.  We intend to advance our cancer studies in ovarian and pancreatic cancer, while seeking to opportunistically participate in other cancer trials that have strong sponsors with financial support."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024

Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×